ClinicalTrials.gg
TerminatedNCT01552434Updated Nov 5, 2026Results posted

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

A Phase 1 interventional study of Bevacizumab and Cetuximab in Advanced Malignant Neoplasm, Castleman Disease and Digestive System Carcinoma, sponsored by M.D. Anderson Cancer Center. Terminated at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by M.D. Anderson Cancer Center · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
\< 75 % participation
Updated Nov 5, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
116
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Castleman Disease with a site in United States — 4 open to participants now, 5 under way, none of them phase 3. Castleman Disease · United States.

Started
2012
the only one that year
Phase 1
5 of 14
none open now
Registered
5th of 14
by date
Lead sponsor
1 of 14
M.D. Anderson Cancer Center

Among the 14 studies in Castleman Disease with a site in United States, this one is the only one that started in 2012, is one of 5 in phase 1, and was the 5th registered.

Castleman Disease

22 studies on the registry are indexed under Castleman Disease; 9 are open to participants now.

Browse Castleman Disease studies →

Open to participants now

4 of the 14 studies in Castleman Disease with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Castleman Disease studies recruiting now, 7 set no upper age limit and none stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Castleman Disease with a site in United States, or all of them as a file.
02

Study summary

This phase I trial studies the side effects and best dose of bevacizumab and temsirolimus alone or in combination with valproic acid or cetuximab in treating patients with a malignancy that has spread to other places in the body or other disease that is not cancerous. Immunotherapy with bevacizumab and cetuximab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as valproic acid, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether bevacizumab and temsirolimus work better when given alone or with valproic acid or cetuximab in treating patients with a malignancy or other disease that is not cancerous.

Read the detailed description

PRIMARY OBJECTIVES:

I. To determine the maximum tolerated doses (MTDs) and dose-limiting toxicities (DLTs) of treatment with bevacizumab and temsirolimus in combination and plus valproic acid or cetuximab.

SECONDARY OBJECTIVES:

I. Preliminary descriptive assessment of anti-tumor efficacy of each combination.

II. Preliminary assessment of the pharmacokinetic, pharmacodynamic markers of target inhibition and correlates of response (optional).

OUTLINE: This is a dose-escalation study of bevacizumab and temsirolimus. Patients are assigned to 1 of 3 treatment groups.

GROUP I: Patients receive temsirolimus intravenously (IV) over 30-60 minutes on days 1, 8, 15, and 22; bevacizumab IV over 30-90 minutes on days 1 and 15; and cetuximab IV over 1-2 hours on days 1, 8, 15, and 22.

GROUP II: Patients receive temsirolimus and bevacizumab as in Group I and valproic acid orally (PO) daily on days 1-7 and 15-21.

GROUP III: Patients receive temsirolimus and bevacizumab as in Group I.

In all groups, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

03

Conditions studied

  • Advanced Malignant Neoplasm
  • Castleman Disease
  • Digestive System Carcinoma
  • Erdheim-Chester Disease
  • Lip and Oral Cavity Carcinoma
  • Lymphangioleiomyomatosis
  • Malignant Endocrine Neoplasm
  • Malignant Female Reproductive System Neoplasm
  • Malignant Male Reproductive System Neoplasm
  • Malignant Neoplasm
  • Malignant Respiratory Tract Neoplasm
  • Malignant Thoracic Neoplasm
  • Malignant Urinary System Neoplasm
  • Mesothelial Neoplasm
  • Metastatic Malignant Neoplasm
  • Metastatic Urothelial Carcinoma
  • Neurofibromatosis Type 2
  • Recurrent Adult Soft Tissue Sarcoma
  • Recurrent Breast Carcinoma
  • Recurrent Childhood Soft Tissue Sarcoma
  • Recurrent Digestive System Carcinoma
  • Recurrent Female Reproductive System Carcinoma
  • Recurrent Male Reproductive System Carcinoma
  • Recurrent Malignant Neoplasm
  • Recurrent Pharyngeal Carcinoma
  • Recurrent Thyroid Gland Carcinoma
  • Refractory Malignant Neoplasm
  • Soft Tissue Neoplasm
  • Stage III Breast Cancer AJCC v7
  • Stage III Pharyngeal Cancer
  • Stage IIIA Breast Cancer AJCC v7
  • Stage IIIB Breast Cancer AJCC v7
  • Stage IIIC Breast Cancer AJCC v7
  • Stage IV Breast Cancer AJCC v6 and v7
  • Stage IV Pharyngeal Cancer
  • Stage IVA Pharyngeal Cancer
  • Stage IVB Pharyngeal Cancer
  • Stage IVC Pharyngeal Cancer
  • Thyroid Gland Neoplasm

Keywords

  • Temsirolimus
  • CCI-779
  • Torisel
  • Bevacizumab
  • Avastin
  • rhuMAb-VEGF
  • Anti-VEGF Monoclonal Antibody
  • Advanced Cancers
  • Advanced Malignancy
  • Metastatic
  • cancer
  • Cetuximab
  • C225
  • Erbitux
  • IMC-C225
  • Valproic Acid
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with advanced or cancer that is to standard therapy, relapsed after standard therapy, or have no standard therapy that induces a complete response of at least 10% or improves survival by at least three months; in addition, patients with disease that are "benign" by pathology, but relentlessly progressive, leading to disability, pain, and premature death in the majority of cases (including, but not limited to lymphangioleiomyomatosis [LAM], type 2 neurofibromatosis [NF], Erdheim Chester disease, and Castleman's disease) may also be considered for enrollment
  • Patients should be at least four weeks from the last day of therapeutic radiation or cytotoxic chemotherapy or from antibody therapy, or at least five half-lives from non-cytotoxic targeted or biologic therapy; patients may have received palliative radiation immediately before (or during) treatment provided radiation is not to the only target lesion available
  • (ECOG) performance status =\< 2
  • >= 60%
  • Lansky performance status of >= 60% for participants 16 years old or younger
  • >= 1,000/mL
  • >= 50,000/mL
  • Creatinine =\< 3 X (ULN)
  • Total =\< 3.0
  • (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =\< 5 X ULN
  • Fasting level of total cholesterol of no more than 350 mg/dL
  • Triglyceride level of no more than 400 mg/dL
  • Women of and men must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days after the last dose
  • Ability to understand and the willingness to sign a written document
  • Patients may not be receiving any other agents and/or any other concurrent anticancer agents or therapies

Exclusion criteria

Exclusion Criteria:

  • Patients with unexplained bleeding within 28 days prior to entering the study
  • Uncontrolled systemic vascular hypertension (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg on medication)
  • Patients with clinically significant cardiovascular disease: History of CVA (cerebrovascular accident) within 6 months, myocardial infarction or unstable angina within 6 months, unstable angina pectoris
  • Pregnant or breast-feeding women
  • History of to bevacizumab, murine products, or any component of the formulation
  • History of hypersensitivity to temsirolimus or its metabolites (including sirolimus), polysorbate 80, or to any component of the formulation
  • History of hypersensitivity to cetuximab, murine products, or any component of the formulation
  • Patients that are taking cytochrome P450 family 3, subfamily A, polypeptide 4 () inducers and/or inhibitors; if a patient has a history of taking CYP3A4 inducers and/or inhibitors prior to enrollment on the protocol, it is strongly recommended that the patient stops the drug and waits at least 5 half-lives of said drug before initiating therapy on protocol
  • Colorectal cancer patients with known v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation (for the arm combining bevacizumab, temsirolimus and cetuximab)
  • Patients who have had major surgery within 6 weeks of enrollment in the study
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
116 participants (actual)

Study arms

  • Experimental
    Group I (temsirolimus, bevacizumab, cetuximab)

    Patients receive temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22; bevacizumab IV over 30-90 minutes on days 1 and 15; and cetuximab IV over 60-120 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

    Biological: Bevacizumab · Biological: Cetuximab · Other: Laboratory Biomarker Analysis · Other: Pharmacological Study · Drug: Temsirolimus

  • Experimental
    Group II (temsirolimus, bevacizumab, valproic acid)

    Patients receive temsirolimus and bevacizumab as in Group I and valproic acid PO on days 1-7 and 15-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

    Biological: Bevacizumab · Other: Laboratory Biomarker Analysis · Other: Pharmacological Study · Drug: Temsirolimus · Drug: Valproic Acid

  • Experimental
    Group III (temsirolimus, bevacizumab)

    Patients receive temsirolimus and bevacizumab as in Group I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

    Biological: Bevacizumab · Other: Laboratory Biomarker Analysis · Other: Pharmacological Study · Drug: Temsirolimus

Interventions

  • BiologicalBevacizumab

    Given IV

    Also known as: Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar QL 1101, BEVACIZUMAB, LICENSE HOLDER UNSPECIFIED, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF

  • BiologicalCetuximab

    Given IV

    Also known as: Cetuximab Biosimilar CMAB009, Chimeric Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225, Chimeric Monoclonal Antibody C225, Erbitux, IMC-C225

  • OtherLaboratory Biomarker Analysis

    Optional correlative studies

  • OtherPharmacological Study

    Optional correlative studies

  • Given IV

    Also known as: CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel

  • Given PO

    Also known as: Depakene, Stavzor, Valproate

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose Limiting Toxicities (DLT)

    A dose limiting toxicity (DLT) is defined as a clinically significant adverse event or abnormal laboratory value assessed as unrelated to disease progression, intercurrent illness, or concomitant medications and occurring during the first cycle on study that meets any of the following criteria: * Grade 3 or 4 non-hematologic toxicity (except nausea and vomiting responsive to appropriate regimens or alopecia) * Any Grade 4 hematologic toxicity lasting \> 14 days despite supportive measures * Any Grade 4 nausea or vomiting \> 5 days despite maximum anti-nausea regimens * Any other Grade 3 non-hematologic toxicity including symptoms/signs of vascular leak or cytokine release syndrome * Any severe or life-threatening complication or abnormality not defined in the NCI-CTCAE that is attributable to the therapy Note: correctable electrolyte imbalances and alopecia are not considered DLTs.

    Time frame: First 28-day cycle

07

Results

Posted Nov 5, 2026

Participant flow

Participant flow — Overall Study
MilestoneArm1/Escalation Dose Level 1Arm1/Escalation Dose Level 2Arm1/Escalation Dose Level 3Arm2/Escalation Dose Level 1Arm2/Escalation Dose Level 2Arm2/Escalation Dose Level 3Arm2/Escalation Dose Level 4Arm2/Escalation Dose Level 5Arm2/Escalation Dose Level 6Arm2/Escalation Dose Level 7Arm2/Escalation Dose Level 8Arm2/Escalation Dose Level 9Arm2/Escalation Dose Level 10Arm3/Escalation Dose Level 1Arm3/Escalation Dose Level 2Arm3/Escalation Dose Level 3Arm3/Escalation Dose Level 4Arm3/Escalation Dose Level 5Arm3/Escalation Dose Level 6Arm3/Escalation Dose Level 7Arm3/Escalation Dose Level 8Arm3/ MTD ExpansionArm3/Ovarian Expansion
Started3162364366337634343634108
Completed3162364366337634343634108
Not completed00000000000000000000000

Outcome measures

PrimaryNumber of Participants With Dose Limiting Toxicities (DLT)

A dose limiting toxicity (DLT) is defined as a clinically significant adverse event or abnormal laboratory value assessed as unrelated to disease progression, intercurrent illness, or concomitant medications and occurring during the first cycle on study that meets any of the following criteria: * Grade 3 or 4 non-hematologic toxicity (except nausea and vomiting responsive to appropriate regimens or alopecia) * Any Grade 4 hematologic toxicity lasting \> 14 days despite supportive measures * Any Grade 4 nausea or vomiting \> 5 days despite maximum anti-nausea regimens * Any other Grade 3 non-hematologic toxicity including symptoms/signs of vascular leak or cytokine release syndrome * Any severe or life-threatening complication or abnormality not defined in the NCI-CTCAE that is attributable to the therapy Note: correctable electrolyte imbalances and alopecia are not considered DLTs.

Time frame:
First 28-day cycle
Reported as:
Count of participants · Participants
Number of Participants With Dose Limiting Toxicities (DLT)
ParticipantsArm1/Escalation Dose Level 1Arm1/Escalation Dose Level 2Arm1/Escalation Dose Level 3Arm2/Escalation Dose Level 1Arm2/Escalation Dose Level 2Arm2/Escalation Dose Level 3Arm2/Escalation Dose Level 4Arm2/Escalation Dose Level 5Arm2/Escalation Dose Level 6Arm2/Escalation Dose Level 7Arm2/Escalation Dose Level 8Arm2/Escalation Dose Level 9Arm2/Escalation Dose Level 10Arm3/Escalation Dose Level 1Arm3/Escalation Dose Level 2Arm3/Escalation Dose Level 3Arm3/Escalation Dose Level 4Arm3/Escalation Dose Level 5Arm3/Escalation Dose Level 6Arm3/Escalation Dose Level 7Arm3/Escalation Dose Level 8Arm3/ MTD ExpansionArm3/Ovarian Expansion
Number of Participants With Dose Limiting Toxicities (DLT)03201001100120000010222

Adverse events

Collected over 13.5 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm1/ Escalation Dose Level 10/3 (0%)2/3 (66.7%)3/3 (100%)
Arm1/ Escalation Dose Level 20/16 (0%)5/16 (31.3%)16/16 (100%)
Arm1/ Escalation Dose Level 30/2 (0%)2/2 (100%)2/2 (100%)
Arm2/Escalation Dose Level 10/3 (0%)1/3 (33.3%)3/3 (100%)
Arm2/Escalation Dose Level 22/6 (33.3%)4/6 (66.7%)6/6 (100%)
Arm2/Escalation Dose Level 30/4 (0%)2/4 (50%)4/4 (100%)
Arm2/Escalation Dose Level 40/3 (0%)1/3 (33.3%)3/3 (100%)
Arm2/Escalation Dose Level 51/6 (16.7%)1/6 (16.7%)6/6 (100%)
Arm2/Escalation Dose Level 60/6 (0%)5/6 (83.3%)6/6 (100%)
Arm2/Escalation Dose Level 70/3 (0%)0/3 (0%)3/3 (100%)
Arm2/Escalation Dose Level 80/3 (0%)2/3 (66.7%)3/3 (100%)
Arm2/Escalation Dose Level 90/7 (0%)6/7 (85.7%)7/7 (100%)
Arm2/Escalation Dose Level 101/6 (16.7%)4/6 (66.7%)5/5 (100%)
Arm3/Escalation Dose Level 10/3 (0%)0/3 (0%)3/3 (100%)
Arm3/Escalation Dose Level 20/4 (0%)2/4 (50%)3/4 (75%)
Arm3/Escalation Dose Level 30/3 (0%)2/3 (66.7%)3/3 (100%)
Arm3/Escalation Dose Level 40/4 (0%)0/4 (0%)4/4 (100%)
Arm3/Escalation Dose Level 50/3 (0%)1/3 (33.3%)2/3 (66.7%)
Arm3/Escalation Dose Level 60/6 (0%)3/6 (50%)6/6 (100%)
Arm3/Escalation Dose Level 70/3 (0%)2/3 (66.7%)3/3 (100%)
Arm3/Escalation Dose Level 80/4 (0%)3/4 (75%)4/4 (100%)
Arm3/Escalation MTD Expansion3/10 (30%)3/10 (30%)10/10 (100%)
Arm3/Ovarian Expansion0/8 (0%)3/8 (37.5%)7/8 (87.5%)
Most frequent serious events
Showing 10 of 55
Most frequent serious events
EventArm1/ Escalation Dose Level 1Arm1/ Escalation Dose Level 2Arm1/ Escalation Dose Level 3Arm2/Escalation Dose Level 1Arm2/Escalation Dose Level 2Arm2/Escalation Dose Level 3Arm2/Escalation Dose Level 4Arm2/Escalation Dose Level 5Arm2/Escalation Dose Level 6Arm2/Escalation Dose Level 7Arm2/Escalation Dose Level 8Arm2/Escalation Dose Level 9Arm2/Escalation Dose Level 10Arm3/Escalation Dose Level 1Arm3/Escalation Dose Level 2Arm3/Escalation Dose Level 3Arm3/Escalation Dose Level 4Arm3/Escalation Dose Level 5Arm3/Escalation Dose Level 6Arm3/Escalation Dose Level 7Arm3/Escalation Dose Level 8Arm3/Escalation MTD ExpansionArm3/Ovarian Expansion
FatigueGeneral disorders0/30/160/20/30/60/40/30/60/6—2/31/70/6—1/40/3—0/30/60/31/40/100/8
PneumoniaInfections and infestations0/30/160/20/30/60/40/30/60/6—0/31/70/6—0/40/3—0/30/62/30/41/100/8
HeadacheNervous system disorders0/30/161/20/30/60/41/30/60/6—0/30/70/6—1/40/3—0/31/60/30/40/100/8
MucositisGastrointestinal disorders0/30/161/20/30/60/40/30/60/6—0/30/70/6—0/40/3—0/30/60/30/40/100/8
HypertensionVascular disorders0/30/161/20/30/60/40/30/60/6—0/30/70/6—0/40/3—0/30/60/30/40/100/8
RashSkin and subcutaneous tissue disorders0/30/161/20/30/60/40/30/60/6—0/30/70/6—0/40/3—0/30/60/30/40/100/8
Wound dehiscenceSkin and subcutaneous tissue disorders1/30/160/20/30/60/40/30/60/6—0/30/70/6—0/40/3—0/30/60/30/40/100/8
Right preseptal orbital abscessInfections and infestations1/30/160/20/30/60/40/30/60/6—0/30/70/6—0/40/3—0/30/60/30/40/100/8
ANC decreasedInvestigations1/30/160/20/30/60/40/30/60/6—0/30/70/6—0/40/3—0/30/60/30/40/100/8
FeverInfections and infestations1/30/160/20/31/60/40/30/61/6—0/30/70/6—0/41/3—0/30/60/30/40/101/8
Most frequent other events
Showing 10 of 146
Most frequent other events
EventArm1/ Escalation Dose Level 1Arm1/ Escalation Dose Level 2Arm1/ Escalation Dose Level 3Arm2/Escalation Dose Level 1Arm2/Escalation Dose Level 2Arm2/Escalation Dose Level 3Arm2/Escalation Dose Level 4Arm2/Escalation Dose Level 5Arm2/Escalation Dose Level 6Arm2/Escalation Dose Level 7Arm2/Escalation Dose Level 8Arm2/Escalation Dose Level 9Arm2/Escalation Dose Level 10Arm3/Escalation Dose Level 1Arm3/Escalation Dose Level 2Arm3/Escalation Dose Level 3Arm3/Escalation Dose Level 4Arm3/Escalation Dose Level 5Arm3/Escalation Dose Level 6Arm3/Escalation Dose Level 7Arm3/Escalation Dose Level 8Arm3/Escalation MTD ExpansionArm3/Ovarian Expansion
HypertriglyceridemiaMetabolism and nutrition disorders3/311/161/23/35/62/43/32/63/62/31/32/73/52/31/40/32/40/32/61/32/47/102/8
FatigueGeneral disorders2/38/162/20/34/61/41/31/61/61/30/31/74/52/32/41/33/42/36/62/33/48/104/8
AnemiaBlood and lymphatic system disorders3/314/162/21/33/63/41/33/62/61/32/30/70/50/30/40/30/40/30/61/32/42/102/8
AST elevationInvestigations3/39/160/23/33/63/41/32/61/61/31/30/71/50/30/41/31/40/30/61/32/44/103/8
ThrombocytopeniaInvestigations0/33/162/21/33/63/40/35/66/63/33/32/73/52/30/42/31/40/33/61/33/44/102/8
HyperglycemiaMetabolism and nutrition disorders3/311/161/22/34/62/40/31/62/62/31/31/73/50/30/40/30/40/32/61/32/42/102/8
HyperkalemiaMetabolism and nutrition disorders1/33/162/21/30/61/40/31/61/61/30/30/70/50/30/40/30/40/30/60/30/41/100/8
HypercholesterolemiaMetabolism and nutrition disorders2/39/160/23/34/63/42/33/64/62/31/31/74/51/31/40/32/40/31/61/31/45/101/8
NauseaGastrointestinal disorders1/33/162/21/33/64/40/32/62/60/31/30/71/51/31/40/31/42/33/61/31/43/103/8
AnorexiaGeneral disorders0/32/162/20/34/62/40/33/63/60/30/33/72/51/31/40/31/41/30/60/31/40/101/8

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Arm1/Escalation Dose Level 1Arm1/Escalation Dose Level 2Arm1/Escalation Dose Level 3Arm2/Escalation Dose Level 1Arm2/Escalation Dose Level 2Arm2/Escalation Dose Level 3Arm2/Escalation Dose Level 4Arm2/Escalation Dose Level 5Arm2/Escalation Dose Level 6Arm2/Escalation Dose Level 7Arm2/Escalation Dose Level 8Arm2/Escalation Dose Level 9Arm2/Escalation Dose Level 10Arm3/Escalation Dose Level 1Arm3/Escalation Dose Level 2Arm3/Escalation Dose Level 3Arm3/Escalation Dose Level 4Arm3/Escalation Dose Level 5Arm3/Escalation Dose Level 6Arm3/Escalation Dose Level 7Arm3/Escalation Dose Level 8Arm3/Escalation Dose Level 9Arm3/Escalation Dose Level 10Total
<=18 years000000000000000000000000
Between 18 and 65 years21223542541146333412236583
>=65 years1400101122230010024114333
Sex: Female, Male
Sex: Female, Male(Participants)Arm1/Escalation Dose Level 1Arm1/Escalation Dose Level 2Arm1/Escalation Dose Level 3Arm2/Escalation Dose Level 1Arm2/Escalation Dose Level 2Arm2/Escalation Dose Level 3Arm2/Escalation Dose Level 4Arm2/Escalation Dose Level 5Arm2/Escalation Dose Level 6Arm2/Escalation Dose Level 7Arm2/Escalation Dose Level 8Arm2/Escalation Dose Level 9Arm2/Escalation Dose Level 10Arm3/Escalation Dose Level 1Arm3/Escalation Dose Level 2Arm3/Escalation Dose Level 3Arm3/Escalation Dose Level 4Arm3/Escalation Dose Level 5Arm3/Escalation Dose Level 6Arm3/Escalation Dose Level 7Arm3/Escalation Dose Level 8Arm3/Escalation Dose Level 9Arm3/Escalation Dose Level 10Total
Female2511323320254133213119865
Male11112320343122210223231051
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm1/Escalation Dose Level 1Arm1/Escalation Dose Level 2Arm1/Escalation Dose Level 3Arm2/Escalation Dose Level 1Arm2/Escalation Dose Level 2Arm2/Escalation Dose Level 3Arm2/Escalation Dose Level 4Arm2/Escalation Dose Level 5Arm2/Escalation Dose Level 6Arm2/Escalation Dose Level 7Arm2/Escalation Dose Level 8Arm2/Escalation Dose Level 9Arm2/Escalation Dose Level 10Arm3/Escalation Dose Level 1Arm3/Escalation Dose Level 2Arm3/Escalation Dose Level 3Arm3/Escalation Dose Level 4Arm3/Escalation Dose Level 5Arm3/Escalation Dose Level 6Arm3/Escalation Dose Level 7Arm3/Escalation Dose Level 8Arm3/Escalation Dose Level 9Arm3/Escalation Dose Level 10Total
Hispanic or Latino0401301010020010000001014
Not Hispanic or Latino0000010453356102301015848
Unknown or Not Reported31222332200000231135334054
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm1/Escalation Dose Level 1Arm1/Escalation Dose Level 2Arm1/Escalation Dose Level 3Arm2/Escalation Dose Level 1Arm2/Escalation Dose Level 2Arm2/Escalation Dose Level 3Arm2/Escalation Dose Level 4Arm2/Escalation Dose Level 5Arm2/Escalation Dose Level 6Arm2/Escalation Dose Level 7Arm2/Escalation Dose Level 8Arm2/Escalation Dose Level 9Arm2/Escalation Dose Level 10Arm3/Escalation Dose Level 1Arm3/Escalation Dose Level 2Arm3/Escalation Dose Level 3Arm3/Escalation Dose Level 4Arm3/Escalation Dose Level 5Arm3/Escalation Dose Level 6Arm3/Escalation Dose Level 7Arm3/Escalation Dose Level 8Arm3/Escalation Dose Level 9Arm3/Escalation Dose Level 10Total
American Indian or Alaska Native000000000000000000000000
Asian0100001100001111010010110
Native Hawaiian or Other Pacific Islander000000000000000000000000
Black or African American0200110010011000101002112
White3922231553364222225337682
More than one race000000000000000000000000
Unknown or Not Reported0401301000000010100001012
Region of Enrollment
Region of Enrollment(participants)Arm1/Escalation Dose Level 1Arm1/Escalation Dose Level 2Arm1/Escalation Dose Level 3Arm2/Escalation Dose Level 1Arm2/Escalation Dose Level 2Arm2/Escalation Dose Level 3Arm2/Escalation Dose Level 4Arm2/Escalation Dose Level 5Arm2/Escalation Dose Level 6Arm2/Escalation Dose Level 7Arm2/Escalation Dose Level 8Arm2/Escalation Dose Level 9Arm2/Escalation Dose Level 10Arm3/Escalation Dose Level 1Arm3/Escalation Dose Level 2Arm3/Escalation Dose Level 3Arm3/Escalation Dose Level 4Arm3/Escalation Dose Level 5Arm3/Escalation Dose Level 6Arm3/Escalation Dose Level 7Arm3/Escalation Dose Level 8Arm3/Escalation Dose Level 9Arm3/Escalation Dose Level 10Total
United States3162364366337634343634108116
08

Study locations

1 site
  • M D Anderson Cancer Center
    Houston, Texas 77030, United States
09

References and documents

Publications

  • Liu X, Kambrick S, Fu S, Naing A, Subbiah V, Blumenschein GR, Glisson BS, Kies MS, Tsimberidou AM, Wheler JJ, Zinner RG, Hong DS, Kurzrock R, Piha-Paul SA. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget. 2016 Apr 26;7(17):23227-38. doi: 10.18632/oncotarget.7594. PubMed 26933802 ↗
  • Nelson BE, Tsimberidou AM, Fu X, Fu S, Subbiah V, Sood AK, Rodon J, Karp DD, Blumenschein G, Kopetz S, Pant S, Piha-Paul SA. A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors. Oncologist. 2023 Dec 11;28(12):1100-e1292. doi: 10.1093/oncolo/oyad158. PubMed 37311055 ↗
  • Piha-Paul SA, Tseng C, Thompson E, Stafford RJ, Le H, Kang L, Fu S, Tsimberidou A, Blumenschein G, Ahnert JR, Slopis JM, Hong D, Naing A, Meric-Bernstam F, Ng CS, Westin S, Sood AK. Phase I study of bevacizumab and temsirolimus combination therapy in advanced malignancies: safety, efficacy, and ovarian cancer expansion. Oncologist. 2026 Feb 5;31(3):oyaf413. doi: 10.1093/oncolo/oyaf413. PubMed 41389341 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2012 to primary completion in May 2026, 162 months.

Results were first posted in Nov 2026, 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2012
First posted
Mar 13, 2012
StartActual
Oct 16, 2012
Primary completionActual
May 8, 2026
CompletionActual
May 8, 2026
Results first posted
Nov 5, 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 5, 2026
Enrollment
154→116
Nov 5, 2026
Primary outcomes
1 added, 2 removed
What changed in the outcomes
  • AddedNumber of Participants With Dose Limiting Toxicities (DLT)Time frame: First 28-day cycle
  • RemovedMaximum tolerated dose (MTD) of bevacizumab, defined as the dose level below the dose at which 2 of 6 patients experience drug-related dose limiting toxicity (DLT)Time frame: 4 weeks
  • RemovedMTD of temsirolimus, defined as the dose level below the dose at which 2 of 6 patients experience DLTTime frame: 4 weeks
Nov 5, 2026
Publications
Results publication added: Liu X, Kambrick S, Fu S, Naing A, Subbiah V, Blumenschein GR, Glisson BS, Kies MS, Tsimberidou AM, Wheler JJ, Zinner RG, Hong DS, Kurzrock R, Piha-Paul SA. Adv… PubMed 26933802 ↗
Nov 5, 2026
Secondary outcomes
3 removed
What changed in the outcomes
  • RemovedAnti-tumor efficacy of each combination (objective response)Time frame: Up to 6 years
  • RemovedLevels of surrogate anti-angiogenesis markersTime frame: Up to week 4 of course 1
  • Removedother outcomeThe properties of the tissue microvasculature.Time frame: Up to week 4 of course 1
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Results posted
    Publications Results publication added: Liu X, Kambrick S, Fu S, Naing A, Subbiah V, Blumenschein GR, Glisson BS, Kies MS, Tsimberidou AM, Wheler JJ, Zinner RG, Hong DS, Kurzrock R, Piha-Paul SA. Adv… PubMed 26933802 ↗
    Enrollment 154→116
    Primary outcomes 1 added, 2 removed
    What changed in the outcomes
    • AddedNumber of Participants With Dose Limiting Toxicities (DLT)Time frame: First 28-day cycle
    • RemovedMaximum tolerated dose (MTD) of bevacizumab, defined as the dose level below the dose at which 2 of 6 patients experience drug-related dose limiting toxicity (DLT)Time frame: 4 weeks
    • RemovedMTD of temsirolimus, defined as the dose level below the dose at which 2 of 6 patients experience DLTTime frame: 4 weeks
    Secondary outcomes 3 removed
    What changed in the outcomes
    • RemovedAnti-tumor efficacy of each combination (objective response)Time frame: Up to 6 years
    • RemovedLevels of surrogate anti-angiogenesis markersTime frame: Up to week 4 of course 1
    • Removedother outcomeThe properties of the tissue microvasculature.Time frame: Up to week 4 of course 1
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT01552434
Responsible party
Sponsor
First posted
Mar 13, 2012
Start date
Oct 16, 2012
Primary completion
May 8, 2026
Completion
May 8, 2026
Results posted
Nov 5, 2026
Last update
Nov 5, 2026

Study contacts

Sarina A Piha-Paul
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bevacizumab · Temsirolimus

Start the discussion